Are disseminated painful follicular lesions with recurrent boils, abscesses, and nodules, possibly rupturing, considered the early (Hurley stage I) stage of hidradenitis suppurativa?

Yes, disseminated painful follicular lesions with recurrent boils, abscesses, and nodules are consistent with early-stage hidradenitis suppurativa (HS), specifically Hurley stage I.

Diagnostic Criteria for HS

The diagnosis of HS requires three clinical findings 1, 2:

1. Typical lesions: painful inflammatory nodules, abscesses, comedones (especially paired/open), sinus tracts, and bridging scars
2. Characteristic locations: predilection for intertriginous sites (axillae, groin, perineum, anogenital region, inframammary areas, buttocks)
3. Chronicity and recurrence: at least 2 lesions in the last 6 months OR lifetime history of >5 lesions 2

Hurley Stage I Classification

Hurley stage I is characterized by recurrent nodules and abscesses with minimal scarring 1. The clinical picture you describe—disseminated painful follicular lesions with recurrent boils, abscesses, and nodules that may or may not rupture—fits precisely within this definition.

Key Features of Early HS:

• Painful inflammatory nodules that recur
• Abscesses that may spontaneously rupture or resolve
• Minimal to no sinus tract formation yet
• Minimal scarring
• Severe pain is characteristic even in early disease 1, 3

Important Clinical Considerations

Pain is a particularly important feature and should be assessed even in early disease 1. The severe pain you describe is consistent with HS from the earliest stages, as pain intensity does not necessarily correlate with Hurley stage.

Common Diagnostic Pitfalls:

Many patients are clinically under-staged 4. A 2025 study using high-resolution ultrasound found that 58.5% of patients had more severe disease on imaging than clinical examination suggested. This means:

• What appears as Hurley stage I clinically may have deeper subclinical involvement
• Early intervention is critical to prevent progression to irreversible tissue damage 5, 6

Disease Progression Pattern:

HS follows a characteristic trajectory 7, 6:

• Early phase: B-cell activation and plasma cell differentiation with inflammatory nodules/abscesses
• Later phase: Th17-mediated chronic inflammation develops
• Advanced phase: irreversible fibrosis, tunnel formation, and extensive scarring

The transition from acute inflammation to chronic tissue remodeling represents a critical window for intervention 6. Once tunnels and extensive fibrosis develop (Hurley stages II-III), medical therapy alone becomes less effective.

Immediate Management Recommendations

For confirmed Hurley stage I disease 1, 2, 8:

1. Document severity: Record Hurley stage, pain score (visual analog scale 0-10), lesion count, and quality of life impact (DLQI)
2. First-line therapy:
   • Topical clindamycin 1% solution twice daily to affected areas
   • Oral tetracycline (doxycycline 100mg or lymecycline 408mg once or twice daily) for 12 weeks
3. Address modifiable factors: smoking cessation and weight management referrals if relevant 2
4. Pain management: NSAIDs or other analgesics as needed
5. Screen for: depression/anxiety and cardiovascular risk factors 2

Reassess at 12 weeks. If inadequate response, escalate to combination clindamycin 300mg + rifampin 300mg twice daily for 10-12 weeks 2, or refer to dermatology for consideration of biologic therapy 8.

Critical Point:

Do not dismiss early disease as "just boils"—the diagnostic delay in HS averages several years 9, during which irreversible tissue damage accumulates. Early recognition and treatment of Hurley stage I disease offers the best opportunity to prevent progression to advanced, surgically-dependent disease.